Late stage colorectal carcinoma is very complicated in its molecular mechanisms. One hundred andnine cases of colorectal carcinomas were analyzed with RFLP method for the allelic deletion of chromosome 17short arms (A...Late stage colorectal carcinoma is very complicated in its molecular mechanisms. One hundred andnine cases of colorectal carcinomas were analyzed with RFLP method for the allelic deletion of chromosome 17short arms (ADCC17p) In this study. The results showed that frs(luency of allelic deletion of chromosome 17short arms (FADC17P) in Dukes’ D stage (95 % ) was higher than those in Dukes’ A, B. C stages (54% 68% ); Fisher’s exact test P <0. 01; FADC17p in colorectal carcinomas with distant metastasis (95 % ) washigher than those without distant metastasis, Fisher’s exact test P <0. 01 However, there were no significant differences in FADC 1 7p between the colorectal carcinomas with lymph node metastasis and those without lymph node metastasis (P >0. 05). Therefore, it is considered that ADC17p is an important diagnosticmarker of late stage colorectal carcinomas, and indicates a poor prognosis.展开更多
目的探讨弥漫大B细胞淋巴瘤(Diffuse large B-cell lymphoma,DLBCL)中TP53基因状态与免疫微环境相关因子CD4蛋白、CD8蛋白、白细胞介素-6(IL-6)水平之间的相关性,以及与各临床病理参数的关系。方法收集174例DLBCL标本,制备组织芯片。应...目的探讨弥漫大B细胞淋巴瘤(Diffuse large B-cell lymphoma,DLBCL)中TP53基因状态与免疫微环境相关因子CD4蛋白、CD8蛋白、白细胞介素-6(IL-6)水平之间的相关性,以及与各临床病理参数的关系。方法收集174例DLBCL标本,制备组织芯片。应用荧光原位杂交(Fluorescence in situ hybridization,FISH)检测TP53等位基因缺失情况,免疫组织化学法检测p53、CD4、CD8蛋白表达情况。收集伴TP53等位基因缺失及未缺失DLBCL患者的血液标本各10例,电化学发光免疫分析法检测IL-6水平。结果TP53等位基因缺失率为21.8%(38/174)。p53蛋白总阳性率为40.8%(71/174)。CD4、CD8蛋白的阳性率分别为1.72%(3/174)、81.03%(141/174)。发生TP53等位基因缺失的病例p53、CD8蛋白的阳性率更高(P<0.05),血清IL-6均值水平也更高(P<0.05)。TP53等位基因缺失、结外侵犯、疾病复发是DLBCL的不良预后独立影响因素(P<0.05)。结论TP53等位基因缺失的DLBCL病例中p53、CD8蛋白阳性率较高,血清IL-6水平升高,总生存率降低,表明TP53等位基因缺失影响DLBCL免疫微环境,是不良预后因子,可能成为免疫检测和/或治疗靶点。展开更多
970299 The application of emergency <sup>99m</sup>Tc-MIBImyocardial imaging in the diagnosis of atypical infarc-tion and during the thrombolytic therapy（five-case re-port）. ZHANG Zhongzheng（张中正）, et...970299 The application of emergency <sup>99m</sup>Tc-MIBImyocardial imaging in the diagnosis of atypical infarc-tion and during the thrombolytic therapy（five-case re-port）. ZHANG Zhongzheng（张中正）, et al. 1st AffiliHosp, Shanxi Med Coll, Taiyuan, 030001. Chin J NuclMed 1997; 17（1）: 28-29.展开更多
文摘Late stage colorectal carcinoma is very complicated in its molecular mechanisms. One hundred andnine cases of colorectal carcinomas were analyzed with RFLP method for the allelic deletion of chromosome 17short arms (ADCC17p) In this study. The results showed that frs(luency of allelic deletion of chromosome 17short arms (FADC17P) in Dukes’ D stage (95 % ) was higher than those in Dukes’ A, B. C stages (54% 68% ); Fisher’s exact test P <0. 01; FADC17p in colorectal carcinomas with distant metastasis (95 % ) washigher than those without distant metastasis, Fisher’s exact test P <0. 01 However, there were no significant differences in FADC 1 7p between the colorectal carcinomas with lymph node metastasis and those without lymph node metastasis (P >0. 05). Therefore, it is considered that ADC17p is an important diagnosticmarker of late stage colorectal carcinomas, and indicates a poor prognosis.
文摘目的探讨弥漫大B细胞淋巴瘤(Diffuse large B-cell lymphoma,DLBCL)中TP53基因状态与免疫微环境相关因子CD4蛋白、CD8蛋白、白细胞介素-6(IL-6)水平之间的相关性,以及与各临床病理参数的关系。方法收集174例DLBCL标本,制备组织芯片。应用荧光原位杂交(Fluorescence in situ hybridization,FISH)检测TP53等位基因缺失情况,免疫组织化学法检测p53、CD4、CD8蛋白表达情况。收集伴TP53等位基因缺失及未缺失DLBCL患者的血液标本各10例,电化学发光免疫分析法检测IL-6水平。结果TP53等位基因缺失率为21.8%(38/174)。p53蛋白总阳性率为40.8%(71/174)。CD4、CD8蛋白的阳性率分别为1.72%(3/174)、81.03%(141/174)。发生TP53等位基因缺失的病例p53、CD8蛋白的阳性率更高(P<0.05),血清IL-6均值水平也更高(P<0.05)。TP53等位基因缺失、结外侵犯、疾病复发是DLBCL的不良预后独立影响因素(P<0.05)。结论TP53等位基因缺失的DLBCL病例中p53、CD8蛋白阳性率较高,血清IL-6水平升高,总生存率降低,表明TP53等位基因缺失影响DLBCL免疫微环境,是不良预后因子,可能成为免疫检测和/或治疗靶点。
文摘970299 The application of emergency <sup>99m</sup>Tc-MIBImyocardial imaging in the diagnosis of atypical infarc-tion and during the thrombolytic therapy（five-case re-port）. ZHANG Zhongzheng（张中正）, et al. 1st AffiliHosp, Shanxi Med Coll, Taiyuan, 030001. Chin J NuclMed 1997; 17（1）: 28-29.
